Session: Antimicrobial Chemotherapy (IDWeek 2012 Meeting)

773	Comparison of Vancomycin and Daptomycin MICs by Testing Method and Media Source for Contemporary Isolates of Methicillin-Resistant Staphylococcus aureus Carmen L. Giltner, PhD. ; April M. Bobenchik, PhD. ; Daniel Z. Uslan, MD, MS ; Janet A. Hindler, MCLS, MT ; Romney M. Humphries, Ph.D.

774	Clinical Evaluation of Pentoxifylline Administration on Amphotericin B Nephrotoxicity Jeremy Sen, PharmD ; Bryan Alexander, PharmD ; Scott Heysell, MD, MPH ; Heather Cox, PharmD ; Costi Sifri, MD ; Brian Wispelwey, MD

775	Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae in Community Hospitals: A Case-Case-Control Study Grace Lee, Pharm.D ; Donna R. Burgess, RPh ; Kurt Winkler, Pharm.D ; Eugene Kreys, Pharm.D ; David S. Burgess, PharmD, FCCP

776	Epidemiology and Risk Factors of Breakthrough Infections in Patients Receiving Carbapenem Therapy Sireethorn Nimitvilai, MD ; Nasikarn Angkasekwinai, MD ; Methee Chayakulkeeree, MD, PhD

777

Comparison of Outcomes and Costs in Patients with Urinary Tract Infections (UTI) or Pneumonia (P) with Treatment Initiated in a Physician Office Infusion Center (POIC) versus those Treated After Hospital Discharge
John S. Adams, MD ; Andrew H. Krinsky, MD ; Jorge R. Bernett, MD ; Robin H. Dretler, MD, FIDSA ; Juan D. Diaz, DO, FACP ; Lucinda J. Van Anglen, PharmD

Posters

IDWeek2012_UTI PNA poster_777_Adams.pdf (714.0 kB)

778	Impact of an Infectious Diseases-Hospitalist Cellulitis Consult Service on Antimicrobial Use and Hospitalization Costs Kristine Johnson, MD, MSc ; Dmitry Kiyatkin, MD ; Karen Daniels, MS, CRNP ; Janet McIntyre, RN, MSN, CPHQ ; Jonathan M. Zenilman, MD, FIDSA Posters for upload.pdf (311.7 kB)

779	Safety and Clinical Outcomes of Daptomycin at Doses of ≥10 mg/kg Kristine C. Willett, PharmD ; Dina Besece, PharmD ; Alicia Desilets, PharmD ; Patrick McDaneld, PharmD ; Jessica Moreno, PharmD ; MinJung Yoon, MPH ; Kenneth C. Lamp, PharmD

780	Antibiotic Timing: Potential Impact on the Correct Diagnosis of Community-Acquired Pneumonia in the Emergency Department Fanny Ita-Nagy, MD ; Marnie Rosenthal, DO, MPH ; Gregg Husk, MD ; Donna Mildvan, MD ; Jorg Ruhe, MD

781

Impact of Guideline-Concordant Antibiotic Therapy in Critically-Ill Healthcare-Associated Pneumonia Patients
Russell T. Attridge, PharmD, MSc ; Christopher R. Frei, PharmD, MSc ; Marcos I. Restrepo, MD, MSc ; Mary Jo V. Pugh ; Antonio Anzueto, MD ; Eric M. Mortensen, MD, MSc

Posters

ID Week 2012 - HCAP in the ICU - Final.pdf (1.3 MB)

783	The State of Infectious Diseases Clinical Trials: A Systematic Analysis of ClinicalTrials.gov Neela D. Goswami, MD ; Christopher Pfeiffer, MD ; John Horton, MS ; Karen Chiswell, PhD ; Asba Tasneem, PhD ; Ephraim Tsalik, MD PhD Posters CT gov_IDSA 2012_Sept20_FINAL.pdf (536.1 kB)

784

Efficacy and safety of moxifloxacin in patients with secondary peritonitis: pooled analysis of four randomised Phase III clinical trials
Jan De Waele, MD PhD ; Jose Tellado ; Jeffrey D. Alder, PhD ; Frank Kruesmann ; Pierre Arvis ; Tajamul Hussain ; Joseph Solomkin, MD

Posters

De Waele_Poster_IDweek_121010_upload.pdf (77.8 kB)

785	Extended Infusion (EI) Compared to Standard Infusion (SI) Cefepime as Empiric Treatment of Febrile Neutropenia (FN): A Pilot Study Rebekah Wrenn, PharmD ; David Cluck, PharmD ; LeAnne Kennedy, PharmD ; Christopher Ohl, MD ; John Williamson, PharmD Posters IDSA Cefepime SI vs EI 2012.pdf (420.7 kB)

786

Evaluation of Clinical and Economic Outcomes when Meropenem and Piperacillin-Tazobactam are Administered as Extended Compared to Intermittent Infusions in Critically Ill Adults
Lacy Ternes, PharmD ; Kati Shihadeh, PharmD ; Kimberly Boeser, Pharm D ; Richard Mandt, PharmD ; Bruce Lohr, PharmD ; Robert Leduc, PhD

Posters

IDWeek Poster.pdf (1.1 MB)

787	Accuracy of Vancomycin Monitoring in Children Becky Ngu, PharmD ; Edmund Capparelli, PharmD ; John S. Bradley, MD, FIDSA ; William Murray, PharmD ; Gale Romanowski, PharmD ; Jennifer Le, PharmD, BCPS-ID, FCCP Posters Poster 787_ Accuracy Vanco PK Modeling _Final.pdf (223.4 kB)

788	Pharmacokinetics (PK) of Daptomycin (DAP) in Pediatric Patients 3 to 24 Months of Age: Implications for Dosing John S. Bradley, MD, FIDSA ; David Benziger, PhD ; Paula Bokesch, MD ; Richard Jacobs, MD

789	A Comparative Evaluation of Adverse Platelet Outcomes among Patients with Acute Bacterial Skin and Skin Structure Infections Receiving Tedizolid Phosphate and Linezolid Thomas Lodise, Pharm D ; Carisa De Anda, PharmD ; Edward Fang, MD

790	Comparison of Treatment Outcomes for Oral Vancomycin Capsules vs. Solution for Severe C. difficile Infection (CDI) Elizabeth A. Neuner, PharmD ; Stephanie Bass, PharmD ; Seth Bauer, PharmD ; Simon Lam, PharmD Posters Vanc cap vs Soln CDI IDSA 2012 Final.pdf (86.8 kB)

791	Therapeutic Drug Monitoring (TDM) of Voriconazole (VCZ) in Pediatric Patients Jennifer M. Pisano, MD ; Emily Landon, MD ; Benjamin D. Brielmaier, PharmD ; Natasha N. Pettit, PharmD, BCPS ; Allison H. Bartlett, MD

792

Outpatient Incidence, Treatment and Recurrence of Clostridium difficile Infection (CDI) in Patients Receiving Intravenous Antibiotic Therapy (IVAB) in a Physician Office Infusion Center (POIC)
Ramesh V. Nathan, MD ; Barry Statner, MD ; Philip Brachman, MD, FACP, FIDSA ; Andrew H. Krinsky, MD ; Robin H. Dretler, MD, FIDSA ; Lucinda J. Van Anglen, PharmD

Posters

IDWeek2012_C Diff Poster _792_Nathan.pdf (825.8 kB)

793

Outcomes Comparison of Intravenous Antimicrobials Provided in a Physician Office Infusion Center (POIC) versus Traditional Home Care (HC) Services
Richard C. Prokesch, MD, FACP, FIDSA ; John S. Adams, MD ; Alfred E. Bacon, III, MD ; Philip Brachman, MD, FACP, FIDSA ; Lucinda J. Van Anglen, PharmD

Posters

IDWeek 2012_POIC vs HC Poster_793_Prokesch.pdf (658.1 kB)

794

Adverse Events and Healthcare Utilization during Home Infusion Therapy with Daptomycin and Vancomycin
Nabin Shrestha, MD, MPH, FIDSA ; Pamela Mason, RN ; Steven Gordon, MD, FIDSA, FSHEA ; Anil K. Jain, MD ; Elizabeth A. Neuner, PharmD ; Benjamin Nutter ; O'Rourke Colin ; Susan J. Rehm, MD

Posters

IDSA poster.pdf (194.0 kB)

795	Effectiveness of Multifaceted Interventions on Rational Use of Antibiotics for Out-Patients at Siriraj Hospital, Bangkok, Thailand Adhiratha Boonyasiri, MD ; Visanu Thamlikitkul, MD

796	Intravenous Antibiotics versus Transition from Intravenous to Oral Antibiotics in E. coli Bacteremic Urinary Tract Infections: A Retrospective Pilot Study Carolyn Mayle, PharmD ; Mandelin Cooper, PharmD ; Valerie Creswell, MD Posters IDSA Poster Final.pdf (446.3 kB)

797	Satisfaction and Outcomes of Patients Discharged on Intravenous Antibiotics With and Without a Formal OPAT Program at a Tertiary Referral Center Katie Sharff, MD ; Joe Fazio, RPh, MHA ; Anne Jacob, MD ; Alex Leahey, MD ; Claire Zeigler, MD ; Penelope Barnes, MBBS, Ph.D

798	Utilization of Intravenous Antimicrobials over a One-Year Period in Physician Office Infusion Centers (POICs) Lucinda J. Van Anglen, PharmD ; Thuy N. Sixt, PharmD ; K. Dale Hooker, PharmD Posters IDWeek 2012_Antimicrobial Utilization _798_Van Anglen.pdf (739.0 kB)

799	Incidence of Adverse Events During Outpatient Antimicrobial Therapy in Patients from an Inner-City, County Teaching Hospital Cole Beeler, MD ; Christina E. K. Chung, PharmD ; Danielle Osterholzer, M.D. ; Eva Muloma, MD ; Sharon Erdman, PharmD Posters Slide1.jpg (3.1 MB)

800

Successful, Cost-Saving Outpatient Parenteral Antimicrobial Therapy (OPAT) Following Hospital Discharge: Early Pilot Study of an Indigent Healthcare Program between a Physician Office Infusion Center (POIC) and Two Tucson Hospitals
Richard M. Mandel, MD, FIDSA ; Clifford P. Martin, MD, DTM&H ; Thuy N. Sixt, PharmD ; Lucinda J. Van Anglen, PharmD ; E. Jolene Patterson, PharmD

Posters

IDWeek 2012 Poster_800_Mandel.pdf (690.1 kB)

801

Adherence to Laboratory Monitory Recommendations and Readmission or Death in a Community-based Parenteral Anti-infective Therapy (CoPAT) Program
Daniel Huck ; Jennifer Ginsberg ; Steven Gordon, MD, FIDSA, FSHEA ; Amy Nowacki, PhD ; Nabin Shrestha, MD, MPH, FIDSA

Posters

Huck_CoPATPoster_IDWeek.pdf (123.2 kB)

802	Outcomes of Patients Receiving Outpatient Parenteral Antibiotic Therapy (OPAT) Long Distances from the Supervising Hospital Katie Sharff, MD ; Kimberly Felder, MSc, PA-C ; Penelope Barnes, MBBS, Ph.D

803	Safety of Midlines vs. PICC lines for Outpatient Parenteral Antibiotic Therapy (OPAT) Geneve Allison, MD ; Xibei Jia, Medical Student ; Yoav Golan, MD MS

804

Outpatient Parenteral Antibiotic Therapy (OPAT): Standardizing Transition from Inpatient to Outpatient Care Through Process Improvement and Positive Deviance
Rahul Anand, M.D. ; Konark Sharma, MD ; Ricardo Postigo, MD ; Brian Kendall, MD ; Sankar Swaminathan, MD

Posters

OPAT Standardizing Transition from Inpatient to Outpatient Care Through Process Improvement and Positive Deviance.pdf (535.4 kB)

805	A national survey of Outpatient Parenteral Anti-microbial Therapy (OPAT) practices in the United States � Focus on patient safety Eavan Muldoon, MB, BCh, MD ; Karen Switkowski, MS, MPH ; Alan Tice, MD, FACP, FIDSA ; David Snydman, MD, FIDSA ; Geneve Allison, MD Posters OPATIDSAfinal.pdf (1.1 MB)

806	Adherence to Standard of Care in the Diagnosis and Treatment of Bacterial Meningitis at Waterbury & St. Mary�s Hospitals David Chia, MD ; Steven Aronin, MD ; Majid Sadigh, MD ; Eugeny Kirsanov

807	Providing Long-Term Intravenous Antimicrobial Therapy to Uninsured Inpatients at an Urban Safety-Net Hospital Katayoun Rezai, MD ; G Itokazu, PharmD ; Robert Glowacki, PharmD ; Laura Wahlfeldt, RN, BSN, ACM ; David Schwartz, MD Posters opat abstract final.pdf (973.6 kB)

808	Risk factors for complications during OPAT therapy Kimberly Felder, MSc, PA-C ; Matthew Dehart, BSc ; Michael Lasarev, MSc ; Lynn Marshall, Ph.D ; Penelope Barnes, MBBS, Ph.D Posters OPAT Complications - Poster.pdf (146.8 kB)

809	Investigation of Nonconvulsive Status Epilepticus Associated with Cefepime Use P Kim, MD MS ; John Farley, M.D., M.P.H. ; T Smith, MD ; Sumathi Nambiar, MD MPH Posters cefepime neurotox poster_9_14_12.pdf (88.2 kB)

810	Piperacillin/Tazobactam-Induced Neutropenia in Children - a Cohort Study Pierre Lemieux, B.Pharm ; Roseline Thibeault, MD ; Jean-Pierre Gr�goire, PhD ; Luc Bergeron, B.Pharm, M.Sc. Posters Poster810_Pip-tazo associated-neutropenia_PLemieux et al_IDWeek2012.pdf (8.3 MB)

811	Infectious Diseases Physician Management of Antibiotic Allergies Lilian Abbo, MD ; Susan E. Beekmann, RN, MPH ; Philip M. Polgreen, MD ; Birgir Johannsson, MD ; Antoine Azar, MD ; Thomas M. Hooton, MD Posters AllergyAbx IDWEEK poster_seb10-02.pdf (796.4 kB)

812

Utilization of Vancomycin Serum Concentrations in the Hospitalized Pediatric Patient
Jennifer Goldman, MD ; Leslie Stach, PharmD, BCPS ; Kevin Mroczka, MHA ; David Williams, MPH ; Stephen De Lurgio, PhD ; Keith Mann, MD, MEd ; Angela Myers, MD, MPH

Posters

poster IDSA 2012 vanc QI_2012_FINAL.pdf (261.9 kB)

813	Evaluation of a Vancomycin Dosing Nomogram based on the Modification of Diet in Renal Disease Equation in Critically Ill Patients Brandy Golenia, PharmD ; Alexander Levine, PharmD ; Iman Moawad, PharmD ; D.Dante Yeh, MD ; Paul Arpino, PharmD Posters 2012_IDWeek_Poster_813-proof.pdf (374.9 kB)

814	Pancreatitis in Tigecycline- and Comparator-Treated Subjects in Phase 3 and 4 Clinical Trials Paul McGovern, MD ; Michele Wible ; Alvaro Quintana Posters PF444-12 Tygacil IDSA Pancreatitis (final 100512).pdf (1.0 MB)

815	The use of N-acetylcysteine for the reversal of hepatotoxicity induced by anti-tuberculosis drugs Heta Javeri, MD, MPH ; Jason E. Bowling, MD ; Gregory Anstead, MD, PhD Posters IDSANACposter10_4_PDF.pdf (257.9 kB)

816	Hypoglycemia in Patients Treated with Linezolid Prabha Viswanathan, MD ; Dmitri Iarikov, MD ; Ronald Wassel, PharmD ; Alma Davidson, MD ; Sumathi Nambiar, MD MPH Posters LZD HYPO poster IDSA 2012.pdf (58.2 kB)

817	Nephrotoxicity Risk Factors among Persons Undergoing Antibiotic-Impregnated Cement Spacer Placement for Treatment of an Infected Joint Erica E. Reed, PharmD, BCPS ; Jessica E. West, MSPH ; Meredith Deutscher, MD

818

Efficacy and Safety of Oral Vancomycin (V) Versus Oral Metronidazole (M) for Treatment of Clostridium difficile Associated Diarrhea (CDAD): Pooled Results from Two Randomized Clinical Trials
Stuart Johnson, MD, FIDSA ; Dale Gerding, MD, FIDSA ; David Davidson, MD ; Thomas J Louie, M D ; Oliver A Cornely, MD, FIDSA ; David Fitts ; Stephen Gelone, PharmD ; Colin Broom, MD

819

Risk Factors Associated with Renal Dysfunction in Children Treated with Intravenous Acyclovir: a Case Control Study
Suchitra Rao, MB, BS ; Mark J Abzug, MD ; Phyllis Carosone-Link, MSPH ; Tori Peterson, PharmD ; Danielle Soranno, MD ; Georgette Siparsky, PhD ; Jason Child, PharmD ; Eric A.F. Simoes, MB BS, DCH, MD

Posters

ACV IDSA abstract 10.4.12.jpg (783.2 kB)

820

A Retrospective Review of Pharyngeal Gonorrhea Clinical Failures to Cefixime in Two STI Clinics in Alberta, Canada
Jennifer Gratrix, RN, MSc ; Joshua Bergman, RN, BScN ; Ron Read, MD ; Marguerite Lovgren, MLT, ART ; Steven J. Drews, PhD ; Ameeta Singh, BMBS, MSc

Posters

Gratrix_GC pharyngeal treatment failures 2007 to 2011_FINAL.pdf (143.1 kB)

821	Incidence of Toxicity with High-Dose Trimethoprim-Sulfamethoxazole in a VA Medical Center Ann Nguyen, Pharm.D. ; Chris Gentry, Pharm.D. ; Rona Furrh, Pharm.D. Posters TMPSMXposterv4.pdf (529.9 kB)